AR075516A1 - Composicion farmaceutica para inhalacion - Google Patents
Composicion farmaceutica para inhalacionInfo
- Publication number
- AR075516A1 AR075516A1 ARP100100474A ARP100100474A AR075516A1 AR 075516 A1 AR075516 A1 AR 075516A1 AR P100100474 A ARP100100474 A AR P100100474A AR P100100474 A ARP100100474 A AR P100100474A AR 075516 A1 AR075516 A1 AR 075516A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhalation
- excipients
- lactose
- premixes
- composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 4
- 229960001375 lactose Drugs 0.000 abstract 4
- 239000008101 lactose Substances 0.000 abstract 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 229960002052 salbutamol Drugs 0.000 abstract 2
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 abstract 1
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 abstract 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013566 allergen Substances 0.000 abstract 1
- 229960004784 allergens Drugs 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 239000004004 anti-anginal agent Substances 0.000 abstract 1
- 230000001078 anti-cholinergic effect Effects 0.000 abstract 1
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- -1 anti-infectives Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 229940124345 antianginal agent Drugs 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 229960005475 antiinfective agent Drugs 0.000 abstract 1
- 239000003434 antitussive agent Substances 0.000 abstract 1
- 229940124584 antitussives Drugs 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229940092705 beclomethasone Drugs 0.000 abstract 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 abstract 1
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 229950010713 carmoterol Drugs 0.000 abstract 1
- 229960003728 ciclesonide Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229960001022 fenoterol Drugs 0.000 abstract 1
- 229960002714 fluticasone Drugs 0.000 abstract 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 229960001021 lactose monohydrate Drugs 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 229960004017 salmeterol Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 235000000346 sugar Nutrition 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229940110309 tiotropium Drugs 0.000 abstract 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composicion farmacéutica para inhalacion. Método para establecer las características de desempeno de dicha composicion y uso de dicha composicion en el tratamiento del asma, de la EPOC, de las alergias, de las enfermedades infecciosas y de las enfermedades del sistema cardiovascular. Reivindicacion 1: Un método para establecer las características de desempeno de una composicion farmacéutica para inhalacion, caracterizado porque comprende los siguientes pasos: a) proveer al menos dos premezclas, cada una de las cuales contiene una mezcla de un ingrediente con actividad farmacéutica y un excipiente apropiado; b) mezclar las al menos dos premezclas; y c) introducir la mezcla en un dispositivo de administracion apropiado, capaz de administrar la fraccion de medicamento en el sistema pulmonar de un paciente, donde la relacion de peso entre los excipientes de las al menos dos premezclas se fija entre 1 y 5. Reivindicacion 2: El método de la reivindicacion 1, caracterizado porque los excipientes usados en las distintas premezclas son iguales o diferentes. Reivindicacion 3: El método de la reivindicacion 2, caracterizado porque los excipientes son diferentes desde el punto de vista químico. Reivindicacion 4: El método de la reivindicacion 2 o 3, caracterizado porque el valor d50 de los excipientes individuales difiere más de 10%, preferiblemente más de 15%, más preferiblemente más de 20%. Reivindicacion 5: El método de una o más de las reivindicaciones precedentes, caracterizado porque los al menos dos ingredientes con actividad farmacéutica se seleccionan del grupo que consiste en ingredientes activos apropiados para la inhalacion, preferiblemente analgésicos, agentes anti-anginales, antialergénicos, antibioticos, antiinfecciosos, antihistamínicos, antiinflamatorios, antitusivos broncodilatadores, drogas anticolinérgicas, hormonas, xantinas, vacunas, proteínas o péptidos terapéuticos y combinaciones de éstos, más preferiblemente albuterol, beclometasona, budesonida, carmoterol, ciclesonida, fenoterol, fluticasona, formoterol, indacaterol, ipratropio, mometasona, salbutamol, salmeterol, tiotropio y sales o solvatos farmacéuticamente aceptables de éstos. Reivindicacion 6: El método de una o más de las reivindicaciones precedentes, caracterizado porque los excipientes se seleccionan del grupo que consiste en los azucares y los sacáridos preferiblemente la lactosa con grado de inhalacion, preferiblemente el a monohidrato de lactosa en forma de lactosa cristalina, lactosa triturada o lactosa micronizada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09153082A EP2221048A1 (en) | 2009-02-18 | 2009-02-18 | Pharmaceutical composition for inhalation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075516A1 true AR075516A1 (es) | 2011-04-06 |
Family
ID=40810348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100474A AR075516A1 (es) | 2009-02-18 | 2010-02-18 | Composicion farmaceutica para inhalacion |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8840930B2 (es) |
| EP (2) | EP2221048A1 (es) |
| JP (1) | JP2012517987A (es) |
| KR (1) | KR20110120283A (es) |
| CN (1) | CN102325523B (es) |
| AR (1) | AR075516A1 (es) |
| AU (1) | AU2010215490B2 (es) |
| BR (1) | BRPI1008598A2 (es) |
| CA (1) | CA2749231C (es) |
| CY (1) | CY1119216T1 (es) |
| DK (1) | DK2398464T3 (es) |
| EA (1) | EA021123B1 (es) |
| ES (1) | ES2607210T3 (es) |
| HR (1) | HRP20170014T1 (es) |
| HU (1) | HUE030618T2 (es) |
| IL (1) | IL214036A (es) |
| LT (1) | LT2398464T (es) |
| MX (1) | MX341250B (es) |
| NZ (1) | NZ594026A (es) |
| PL (1) | PL2398464T3 (es) |
| PT (1) | PT2398464T (es) |
| RS (1) | RS55527B1 (es) |
| RU (1) | RU2493833C2 (es) |
| SI (1) | SI2398464T1 (es) |
| SM (2) | SMT201700095T1 (es) |
| UA (1) | UA102138C2 (es) |
| WO (1) | WO2010094731A2 (es) |
| ZA (1) | ZA201105532B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| CN103269694A (zh) | 2010-10-12 | 2013-08-28 | 西普拉有限公司 | 药物组合物 |
| CN102451173B (zh) * | 2010-10-22 | 2015-02-18 | 山东新时代药业有限公司 | 噻托溴铵胶囊型吸入粉雾剂 |
| TR201205852A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Geliştirilmiş yeni kuru toz formülasyonu. |
| TR201105367A2 (tr) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Akış özellikleri geliştirilmiş bir kuru toz formülasyonu. |
| US20150202321A1 (en) * | 2012-08-14 | 2015-07-23 | Newgen Biopharma Corp. | Compositions comprising chitosan-drug conjugates and methods of making and using the same |
| CN103860525B (zh) * | 2012-12-11 | 2016-04-06 | 天津药物研究院 | 一种含有效成分安立生坦的胶囊型吸入粉雾剂及其制备工艺 |
| MX2015015132A (es) * | 2013-04-29 | 2016-02-18 | Sanofi Sa | Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen. |
| MX2015015150A (es) * | 2013-04-29 | 2016-02-18 | Sanofi Sa | Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen. |
| WO2014202513A1 (en) * | 2013-06-17 | 2014-12-24 | Arven Ilac Sanayi Ve Ticaret A.S. | Inhalation composition filling method |
| UA118861C2 (uk) * | 2013-12-06 | 2019-03-25 | Оріон Корпорейшн | Спосіб отримання сухих порошкових композицій для інгаляцій |
| CN103784449A (zh) * | 2014-02-18 | 2014-05-14 | 青岛市城阳区人民医院 | 一种包含茚达特罗和噻托溴铵的药物组合产品 |
| PT109030B (pt) * | 2015-12-15 | 2019-09-25 | Hovione Farmaciência, S.A. | Preparação de partículas inaláveis de zafirlucaste |
| CN107095875B (zh) * | 2016-02-23 | 2022-03-18 | 天津金耀集团有限公司 | 一种昔奈酸沙美特罗丙酸氟替卡松复方粉吸入剂组合物 |
| CN108066329B (zh) * | 2016-11-11 | 2021-11-16 | 江苏恒瑞医药股份有限公司 | 一种吸入用氟替卡松或其衍生物的微粒的制备方法 |
| CN107823193B (zh) * | 2017-11-16 | 2021-02-05 | 广州迈达康医药科技有限公司 | 一种阿地溴铵吸入型粉雾剂及其制备方法 |
| PT3833964T (pt) | 2018-08-07 | 2023-08-17 | Norton Waterford Ltd | Aplicação de espetroscopia de raman para o fabrico de pós de inalação |
| CN116615201A (zh) | 2020-08-14 | 2023-08-18 | 诺顿（沃特福特）有限公司 | 丙酸氟替卡松和硫酸沙丁胺醇的可吸入制剂 |
| WO2022146255A1 (en) * | 2020-12-31 | 2022-07-07 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | A process for the preparation of dry powder compositions for inhalation |
| US20250213803A1 (en) * | 2023-12-27 | 2025-07-03 | Kindeva Drug Delivery L.P. | Dry powder formulations, dose containers and inhalers containing the same, and methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4140689B4 (de) * | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalationspulver und Verfahren zu ihrer Herstellung |
| KR100589926B1 (ko) | 1997-09-29 | 2006-06-15 | 넥타르 테라퓨틱스 | 천공된 미립자 및 사용 방법 |
| ITMI991582A1 (it) * | 1999-07-16 | 2001-01-16 | Chiesi Farma Spa | Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala |
| DE19947235A1 (de) * | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten |
| GB0012260D0 (en) * | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
| WO2003024396A2 (en) | 2001-09-17 | 2003-03-27 | Glaxo Group Limited | Dry powder medicament formulations |
| US20050201948A1 (en) * | 2002-04-12 | 2005-09-15 | Ellison Mark Jason H | Excipient for use in dry powder inhalation preparations |
| GB2395900A (en) * | 2002-12-04 | 2004-06-09 | Elan Drug Delivery Ltd | Therapeutic composition for respiratory delivery |
| US20040152720A1 (en) * | 2002-12-20 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powdered medicaments containing a tiotropium salt and salmeterol xinafoate |
| CA2550841C (en) * | 2004-02-06 | 2012-10-02 | Meda Pharma Gmbh & Co. Kg | Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases |
| CN101175480A (zh) * | 2005-03-16 | 2008-05-07 | 伊兰制药国际有限公司 | 纳米微粒白三烯受体拮抗剂/皮质类固醇制剂 |
| GB0714134D0 (en) * | 2007-07-19 | 2007-08-29 | Norton Healthcare Ltd | Dry-powder medicament |
-
2009
- 2009-02-18 EP EP09153082A patent/EP2221048A1/en not_active Withdrawn
-
2010
- 2010-02-18 PL PL10711610T patent/PL2398464T3/pl unknown
- 2010-02-18 US US13/202,081 patent/US8840930B2/en not_active Expired - Fee Related
- 2010-02-18 ES ES10711610.5T patent/ES2607210T3/es active Active
- 2010-02-18 AU AU2010215490A patent/AU2010215490B2/en not_active Ceased
- 2010-02-18 CN CN201080007956.4A patent/CN102325523B/zh not_active Expired - Fee Related
- 2010-02-18 MX MX2011008659A patent/MX341250B/es active IP Right Grant
- 2010-02-18 JP JP2011549610A patent/JP2012517987A/ja active Pending
- 2010-02-18 HU HUE10711610A patent/HUE030618T2/en unknown
- 2010-02-18 CA CA2749231A patent/CA2749231C/en not_active Expired - Fee Related
- 2010-02-18 AR ARP100100474A patent/AR075516A1/es unknown
- 2010-02-18 HR HRP20170014TT patent/HRP20170014T1/hr unknown
- 2010-02-18 BR BRPI1008598A patent/BRPI1008598A2/pt not_active Application Discontinuation
- 2010-02-18 LT LTEP10711610.5T patent/LT2398464T/lt unknown
- 2010-02-18 KR KR1020117018559A patent/KR20110120283A/ko not_active Ceased
- 2010-02-18 UA UAA201110089A patent/UA102138C2/uk unknown
- 2010-02-18 EA EA201190108A patent/EA021123B1/ru not_active IP Right Cessation
- 2010-02-18 PT PT107116105T patent/PT2398464T/pt unknown
- 2010-02-18 EP EP10711610.5A patent/EP2398464B1/en active Active
- 2010-02-18 RU RU2011133322/15A patent/RU2493833C2/ru not_active IP Right Cessation
- 2010-02-18 NZ NZ594026A patent/NZ594026A/xx not_active IP Right Cessation
- 2010-02-18 SM SM20170095T patent/SMT201700095T1/it unknown
- 2010-02-18 DK DK10711610.5T patent/DK2398464T3/en active
- 2010-02-18 SI SI201031353A patent/SI2398464T1/sl unknown
- 2010-02-18 WO PCT/EP2010/052026 patent/WO2010094731A2/en not_active Ceased
- 2010-02-18 RS RS20161193A patent/RS55527B1/sr unknown
-
2011
- 2011-07-12 IL IL214036A patent/IL214036A/en not_active IP Right Cessation
- 2011-07-27 ZA ZA2011/05532A patent/ZA201105532B/en unknown
-
2016
- 2016-12-23 CY CY20161101340T patent/CY1119216T1/el unknown
-
2017
- 2017-02-10 SM SM201700095T patent/SMT201700095B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075516A1 (es) | Composicion farmaceutica para inhalacion | |
| ES2687751T3 (es) | Tratamiento de enfermedades respiratorias | |
| ES2270806T3 (es) | Combinaciones de formoterol y de una sal de tiotropio. | |
| Parumasivam et al. | Dry powder inhalable formulations for anti-tubercular therapy | |
| JP2012517987A5 (ja) | 吸入用の医薬組成物のｆｐｄ特性を設定する方法 | |
| HUP0200852A2 (en) | Combinations of formoterol and fluticasone propionate for asthma | |
| AR101593A2 (es) | Formulación superfina de formoterol | |
| AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
| AR038641A1 (es) | Formulacion superfina de formoterol | |
| CN103501781B (zh) | 吡咯糖用于治疗心动过速的用途 | |
| RU2006132036A (ru) | Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей | |
| WO2002011711A3 (en) | Formulations of mometasone and a bronchodilator for pulmonary administration | |
| JP2013531056A5 (es) | ||
| FI2265257T4 (fi) | Aklidiniumia käsittävä inhalaatiokoostumus kroonisen keuhkoahtaumataudin hoitamiseksi | |
| BRPI0508170A (pt) | formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem | |
| ES2775606T3 (es) | Furoato de fluticasona en el tratamiento de la EPOC | |
| JP2015519356A5 (es) | ||
| NZ627837A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| JP2019528316A5 (es) | ||
| KR20070042917A (ko) | 소아 천식의 치료 | |
| WO2005044186A3 (en) | Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same | |
| BR0306663A (pt) | Formulação de salmeterol superfino | |
| UY28589A1 (es) | Nuevas sales de tiotropio, procedimientos para su preparación , así como formulaciones medicamentosas que las contienen | |
| JP2004529108A5 (es) | ||
| RU2020112519A (ru) | Ингалятор и сетка для ингалятора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |